

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

01 Jun 2026

### Effects of topical gel Silymarin versus placebo as an adjuvant therapy on pain management in patients with painful diabetic neuropathy: a double-blind randomized clinical trial

#### Protocol summary

##### Study aim

To assess the effect of topical gel Silymarin versus placebo as an adjuvant therapy on pain management in patients with painful diabetic neuropathy

##### Design

This is a Phase III double-blind randomized clinical trial with a control group with parallel groups, in which eligible patients will be randomly assigned to the intervention and control groups using block randomization.

##### Settings and conduct

This study will be conducted at the Beheshti Hospital in Hamadan city, involving 50 eligible patients with painful diabetic neuropathy. The patients will be randomly assigned to the intervention and control groups through the block randomization. This trial will be double-blinded.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age of 18 to 65 years Diabetes mellitus type 1 or 2 Painful diabetic neuropathy Exclusion criteria: Pregnancy or breastfeeding Drug abuse Nondiabetic neuropathy Diabetic ulcer Liver or kidney disease

##### Intervention groups

Intervention group: Pregabalin 75 mg tablet at night plus 3% silymarin topical gel twice a day for 2 months Control group: Pregabalin 75 mg tablet at night plus placebo topical gel twice a day for 2 months

##### Main outcome variables

Primary outcome: Pain score, quality of life score, Secondary outcome: Local complication (redness, itching)

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20120215009014N501**

Registration date: **2024-02-29, 1402/12/10**

Registration timing: **prospective**

Last update: **2024-02-29, 1402/12/10**

Update count: **0**

##### Registration date

2024-02-29, 1402/12/10

##### Registrant information

###### Name

Jalal Poorolajal

###### Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 81 1838 0090

###### Email address

poorolajal@umsha.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2024-03-25, 1403/01/06

##### Expected recruitment end date

2024-08-15, 1403/05/25

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effects of topical gel Silymarin versus placebo as an adjuvant therapy on pain management in patients with

painful diabetic neuropathy: a double-blind randomized clinical trial

#### Public title

Effects of topical gel Silymarin versus placebo as an adjuvant therapy on pain management in patients with painful diabetic neuropathy

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

Age of 18 to 65 years Diabetes mellitus type 1 or 2 Painful diabetic neuropathy

##### Exclusion criteria:

Pregnancy or breastfeeding Drug abuse Nondiabetic neuropathy Diabetic ulcer Liver or kidney disease

#### Age

From **18 years** old to **65 years** old

#### Gender

Both

#### Phase

3

#### Groups that have been masked

- Participant
- Outcome assessor

#### Sample size

Target sample size: **50**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

In this study, random assignment of patients to the intervention and control groups will be carried out using block randomization. To achieve this, four sheets of paper will be prepared - two with the name of the intervention and two with the name of the control. These paper sheets will be pooled and placed in a container. Patients will be selected one at a time without replacement, and for each patient, a paper sheet will be randomly drawn from the container. After each draw, the paper sheets will be returned to the container, and the process will be repeated until the desired sample size is reached.

#### Blinding (investigator's opinion)

Double blinded

#### Blinding description

Both the medications and placebos will have the same shape. Consequently, patients will remain unaware of the type of intervention they receive. Moreover, the randomization process will be conducted by a separate individual from the one who examines the patients, ensuring that the examining person remains unaware of the intervention. The analyzer responsible for evaluating the trial's results will also be kept blind to the type of interventions. Therefore, the trial will be conducted as a double-blind study.

#### Placebo

Used

#### Assignment

Parallel

#### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Hamadan University of Medical Sciences

##### Street address

Vice-chancellor for Research and Technology, Hamadan University of Medical Sciences, Fahmideh Ave

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

#### Approval date

2024-02-24, 1402/12/05

#### Ethics committee reference number

IR.UMSHA.REC.1402.727

## Health conditions studied

### 1

#### Description of health condition studied

Painful diabetic neuropathy

#### ICD-10 code

E08.40

#### ICD-10 code description

Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified

## Primary outcomes

### 1

#### Description

Pain score

#### Timepoint

Before intervention and one and two months later

#### Method of measurement

Using visual analog scale (VAS)

### 2

#### Description

Quality of life score

#### Timepoint

Before the intervention and one and two months later

#### Method of measurement

Using the World Health Organization Quality of Life Questionnaire

## Secondary outcomes

### 1

#### Description

Local complication (redness, itching)

#### Timepoint

One and two months later the intervention

#### Method of measurement

By taking history and clinical examination

## Intervention groups

### 1

#### Description

Intervention group: Pregabalin 75 mg tablet at night plus 3% silymarin topical gel twice a day for 2 months

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Pregabalin 75 mg tablet at night plus placebo topical gel twice a day for 2 months

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Beheshti Hospital in Hamadan city

##### Full name of responsible person

Mohammad Reza Khodarahmi Ghahnavieh

##### Street address

Beheshti Hospital, Eram Ave.

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

##### Phone

+98 81 3838 0283

##### Email

mkh.1999.94@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Hamedan University of Medical Sciences

##### Full name of responsible person

Dr. Reza Shokoohi

##### Street address

Hamadan University of Medical Sciences, Fahmideh Ave

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

##### Phone

+98 81 3838 0717

##### Email

info.research@umsha.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Hamedan University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Hamedan University of Medical Sciences

##### Full name of responsible person

Mohammad Reza Khodarahmi Ghahnavieh

##### Position

Student of Pharmacy

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Medical Pharmacy

##### Street address

School of Pharmacy, Hamadan University of Medical Sciences, Fahmideh Ave.

##### City

Hamadan

##### Province

Hamadan

##### Postal code

6517838695

##### Phone

+98 81 3838 0572

##### Email

mkh.1999.94@gmail.com

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Shahabodin Emami

**Position**

Pharmacologist

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Medical Pharmacy

**Street address**

School of Pharmacy, Hamadan University of Medical Sciences, Fahmideh Ave.

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0572

**Email**

ha\_emami@yahoo.com

**Person responsible for updating data****Contact****Name of organization / entity**

Hamedan University of Medical Sciences

**Full name of responsible person**

Dr. Jalal Poorolajal

**Position**

Professor of Epidemiology

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Epidemiology

**Street address**

School of Public Health, Hamadan University of Medical Sciences, Fahmideh Ave

**City**

Hamadan

**Province**

Hamadan

**Postal code**

6517838695

**Phone**

+98 81 3838 0090

**Email**

poorolajal@umsha.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available